Springer Science and Business Media LLC
Safety and Efficacy of Hizentra ® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies
Publication
, Preprint
Patel, NC; Torgerson, T; Thakar, M; Younger, EM; Sriar, P; Pozos, T; Buckley, R; Morris, D; Vilkama, D; Heimall, J
November 7, 2022
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Patel, N. C., Torgerson, T., Thakar, M., Younger, E. M., Sriar, P., Pozos, T., … Heimall, J. (2022). Safety and Efficacy of Hizentra ® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies. Springer Science and Business Media LLC. https://doi.org/10.21203/rs.3.rs-2216817/v1
Patel, Niraj C., Troy Torgerson, Monika Thakar, Elizabeth M. Younger, Panida Sriar, Tamara Pozos, Rebecca Buckley, David Morris, Diana Vilkama, and Jennifer Heimall. “Safety and Efficacy of Hizentra ® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies.” Springer Science and Business Media LLC, November 7, 2022. https://doi.org/10.21203/rs.3.rs-2216817/v1.
Patel NC, Torgerson T, Thakar M, Younger EM, Sriar P, Pozos T, et al. Safety and Efficacy of Hizentra ® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies. Springer Science and Business Media LLC. 2022.
Patel, Niraj C., et al. “Safety and Efficacy of Hizentra ® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies.” Springer Science and Business Media LLC, 7 Nov. 2022. Crossref, doi:10.21203/rs.3.rs-2216817/v1.
Patel NC, Torgerson T, Thakar M, Younger EM, Sriar P, Pozos T, Buckley R, Morris D, Vilkama D, Heimall J. Safety and Efficacy of Hizentra ® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies. Springer Science and Business Media LLC. 2022.